








Our Company

CONSULTING



-  Benchmarking
-  Competitive Intelligence
-  Market Assessment
-  Forecasting
-  Portfolio
-  Financial Analysis
-  Network of Experts

*Data Driven
Design and
Solutions*

*The Right Expertise for
Your Business Needs*

DATA SERVICES




Real-time access to all historical versions of
More than *100,000 industry-sponsored clinical trials* covering over *1,000,000 versions* across over *~70 data elements*



Proprietary Data Included

- ✓ clean company names
- ✓ mapped to over 1,600 tickers
- ✓ clean active ingredient
- ✓ mechanism of action
- ✓ novel drug / target
- ✓ disease area
- ✓ biomarkers
- ✓ endpoints





Capturing the Biotech & Pharmaceutical R&D Landscape

100,000+ Clinical Trials

With more than 1M Biotech & pharmaceutical company R&D records



1,600 Ticker Symbols

Ticker symbols mapped to public companies



130+

Data Elements



Unlocking the R&D landscape and driving predictions

20+

Years of Data



Two decades of biotech and pharmaceutical company R&D data to generate signal


10K+

Products



4,400

Disease Areas



The Impact of Our Data Processing

COMPANY NAME

Clinical Trial Raw Value	BEAM Name Value	Ticker
Glaxo Group Ltd	GlaxoSmithKline	GSK
GLAXO SMITH KLINE RESEARCH & DEVELOPMENT LTD	GlaxoSmithKline	GSK
GLAXO SMITHKLINE	GlaxoSmithKline	GSK
Glaxo SmithKline Research and Development Limited	GlaxoSmithKline	GSK
GlaxoSmithKline	GlaxoSmithKline	GSK
GlaxoSmithKline Biologicals	GlaxoSmithKline	GSK
GLAXOSMITHKLINE BIOLOGICALS	GlaxoSmithKline	GSK
GlaxoSmithKline Biologicals S.A.	GlaxoSmithKline	GSK
& Johnson Pharmaceutical Research & Development, L.L.C.	Johnson & Johnson	JNJ
Janssen Alzheimer Immunotherapy	Johnson & Johnson	JNJ
JANSSEN Alzheimer Immunotherapy Research & Development, LLC	Johnson & Johnson	JNJ
Janssen Pharmaceutica	Johnson & Johnson	JNJ
Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium	Johnson & Johnson	JNJ
Johnson & Johnson Pharamceutical Resarch & Development, L.L.C	Johnson & Johnson	JNJ
Johnson & Johnson Pharamceutical Research & Development, L.L.C.	Johnson & Johnson	JNJ
Pfizer	Pfizer	PFE
Pfizer Global Research & Development	Pfizer	PFE
Pfizer Global Research and Development	Pfizer	PFE
Pfizer Inc	Pfizer	PFE
PFIZER INC	Pfizer	PFE
Pfizer Inc (235 East 42nd Street, New York, New York 10017)	Pfizer	PFE
Pfizer Inc 235 East 42nd Street New York, NY 10017	Pfizer	PFE
Pfizer Inc 235 East 42nd Street, New York, NY10017	Pfizer	PFE

PRODUCT NAME

Clinical Trial Raw Value	BEAM Name Value	Mechanism of Action
rifampin	rifampicin	CYP3A4 Activator
rifadin	rifampicin	CYP3A4 Activator
rimactane	rifampicin	CYP3A4 Activator
rifampicine	rifampicin	CYP3A4 Activator
rimactazid	rifampicin	CYP3A4 Activator
rifinah	rifampicin	CYP3A4 Activator
sutent	sunitinib	TK Inhibitor
su-011248	sunitinib	TK Inhibitor
su011248	sunitinib	TK Inhibitor
su 011248	sunitinib	TK Inhibitor
mdx-1106	nivolumab	PD-1 Inhibitor
ono-4538	nivolumab	PD-1 Inhibitor
opdivo	nivolumab	PD-1 Inhibitor
bms936558	nivolumab	PD-1 Inhibitor
bms 936558	nivolumab	PD-1 Inhibitor
bms-936558	nivolumab	PD-1 Inhibitor
arn-509	apalutamide	AR Antagonist
arn509	apalutamide	AR Antagonist
jn-56021927	apalutamide	AR Antagonist

**We clean your data
so you can focus on modeling**



Popular Data Elements Offered Beyond the Clinical Trial Data



Biomarkers

Oncology biomarkers have been added to the database and are currently in test. Our biomarker library will continue to evolve based on the needs of our clients



Novel Therapy

If a mechanism of action is not currently marketed, then the therapy will be designated as novel



Novel Treatment Flags

If a product has not been approved by the FDA it will be labeled as novel



Endpoints & Acronyms

Endpoints and their acronyms will be collected from the trial data for filtering and reporting needs



BEAM Point in Time Provides Full History of Data for Your Models

1) Initial thinking for the trial Posted on 1/23/2018

3) Recruitment timing for this trial

5) Novel Drug Flag indicating risk and value of treatment being studied

nct	Last Update Posted	OverallStatus	Study Start	Primary Completion	BEAM sponsors name	BEAM sponsors ticker	Study Phase	BEAM disease area	BEAM treatments name	BEAM treatments target	BEAM novel Drug	Enrollment	Enrollment type
NCT03407482	1/23/2018	Recruiting	1/11/2018	4/9/2020	Genentech	DNA	Phase 2	Lupus Erythematosus, Systemic	Fenebrutinib	Btk Inhibitor	Yes	240	Anticipated
NCT03407482	2/7/2018	Recruiting	1/11/2018	4/9/2020	Genentech	DNA	Phase 2	Lupus Erythematosus, Systemic	Fenebrutinib	Btk Inhibitor	Yes	240	Anticipated
NCT03407482	2/28/2018	Recruiting	1/11/2018	4/9/2020	Genentech	DNA	Phase 2	Lupus Erythematosus, Systemic	Fenebrutinib	Btk Inhibitor	Yes	240	Anticipated
NCT03407482	3/13/2018	Recruiting	1/11/2018	4/9/2020	Genentech	DNA	Phase 2	Lupus Erythematosus, Systemic	Fenebrutinib	Btk Inhibitor	Yes	240	Anticipated
NCT03407482	4/10/2018	Recruiting	1/11/2018	4/9/2020	Genentech	DNA	Phase 2	Lupus Erythematosus, Systemic	Fenebrutinib	Btk Inhibitor	Yes	240	Anticipated
NCT03407482	6/7/2018	Recruiting	1/11/2018	4/9/2020	Genentech	DNA	Phase 2	Lupus Erythematosus, Systemic	Fenebrutinib	Btk Inhibitor	Yes	240	Anticipated
NCT03407482	7/13/2018	Recruiting	1/9/2018	4/9/2020	Genentech	DNA	Phase 2	Lupus Erythematosus, Systemic	Fenebrutinib	Btk Inhibitor	Yes	240	Anticipated
NCT03407482	7/17/2018	Recruiting	1/9/2018	4/9/2020	Genentech	DNA	Phase 2	Lupus Erythematosus, Systemic	Fenebrutinib	Btk Inhibitor	Yes	240	Anticipated
NCT03407482	9/26/2018	Recruiting	1/9/2018	4/9/2020	Genentech	DNA	Phase 2	Lupus Erythematosus, Systemic	Fenebrutinib	Btk Inhibitor	Yes	240	Anticipated
NCT03407482	10/30/2018	Recruiting	1/9/2018	4/9/2020	Genentech	DNA	Phase 2	Lupus Erythematosus, Systemic	Fenebrutinib	Btk Inhibitor	Yes	240	Anticipated
NCT03407482	12/20/2018	Recruiting	1/9/2018	4/9/2020	Genentech	DNA	Phase 2	Lupus Erythematosus, Systemic	Fenebrutinib	Btk Inhibitor	Yes	240	Anticipated
NCT03407482	2/15/2019	Recruiting	1/9/2018	4/9/2020	Genentech	DNA	Phase 2	Lupus Erythematosus, Systemic	Fenebrutinib	Btk Inhibitor	Yes	240	Anticipated
NCT03407482	2/28/2019	Recruiting	1/9/2018	4/9/2020	Genentech	DNA	Phase 2	Lupus Erythematosus, Systemic	Fenebrutinib	Btk Inhibitor	Yes	240	Anticipated
NCT03407482	4/5/2019	Recruiting	1/9/2018	4/9/2020	Genentech	DNA	Phase 2	Lupus Erythematosus, Systemic	Fenebrutinib	Btk Inhibitor	Yes	240	Anticipated
NCT03407482	10/10/2019	Active, not recruiting	1/9/2018	4/10/2020	Genentech	DNA	Phase 2	Lupus Erythematosus, Systemic	Fenebrutinib	Btk Inhibitor	Yes	160	Actual
NCT03407482	11/4/2019	Active, not recruiting	1/9/2018	4/10/2020	Genentech	DNA	Phase 2	Lupus Erythematosus, Systemic	Fenebrutinib	Btk Inhibitor	Yes	160	Actual
NCT03407482	2/17/2020	Completed	1/9/2018	11/20/2019	Genentech	DNA	Phase 2	Lupus Erythematosus, Systemic	Fenebrutinib	Btk Inhibitor	Yes	160	Actual

2) Most recent thinking for the trial last entered on 2/17/2020


4) Primary Completion date five months early could have been easily predicted using primary outcome measures (56 weeks)

6) Shift to Actual aligned with Overall status and indicator to switch timing prediction to be based on outcome measures




blue data columns represent BEAM augmented data

Innovation Index – How novel is the pipeline by Company & Disease




The innovation index is a key indicator for predicting value and risk and can be further summarized at the company and disease area level to evaluate expected growth and value by company.




**Finding a
needle in
the haystack**

Timing is Everything



Applying Risk and Value With BEAM Data



Beau Bush – President and founder of OZMOSI



Beau Bush brings to every client a rich background in predictive analytics, risk assessments, and valuation models for the pharmaceutical industry. He has more than 15 years of experience in developing data-based business and investment strategies, including extensive experience preparing and delivering senior-level summaries and recommendations for global investment and growth strategies.

After more than a decade working on new product development, Beau left his position at Johnson & Johnson in 2013 when he saw the opportunity to engage more directly with an increasingly complex and dynamic healthcare market by building a team of experts. With newly

emerging business models and increasing complexity in drug development making it more and more difficult to predict the impact of new products—or decide which life cycle strategies to pursue—Beau envisioned a company that could bring clarity and confidence to the investment decisions that shape tomorrow's pharmaceutical products.

Beau has a BS in biology from Rutgers University and has worked in several industries, including finance, pharmaceuticals, marine biology, environmental science, and business consulting. He brings to Ozmosi a deep understanding and broad knowledge of global market valuation and healthcare product development, as well as an extensive network of industry experts.